Literature DB >> 10727448

The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions.

K V Vijayan1, P J Goldschmidt-Clermont, C Roos, P F Bray.   

Abstract

Genetic factors are believed to influence the development of arterial thromboses. Because integrin alpha(IIb)beta(3) plays a crucial role in thrombus formation, we analyzed receptor adhesive properties using Chinese hamster ovary and human kidney embryonal 293 cells overexpressing the Pl(A1) or Pl(A2) polymorphic forms of alpha(IIb)beta(3). Soluble fibrinogen binding was no different between Pl(A1) and Pl(A2) cells, either in a resting state or when alpha(IIb)beta(3) was activated with anti-LIBS6. Pl(A1) and Pl(A2) cells bound equivalently to immobilized fibronectin. In contrast, significantly more Pl(A2) cells bound to immobilized fibrinogen in an alpha(IIb)beta(3)-dependent manner than did Pl(A1) cells. Disruption of the actin cytoskeleton by cytochalasin D abolished the increased binding of Pl(A2) cells. Compared with Pl(A1) cells, Pl(A2) cells exhibited a greater extent of polymerized actin and cell spreading, enhanced tyrosine phosphorylation of pp125(FAK), and greater fibrin clot retraction. These adhesion differences appear to depend on a signaling mechanism sensitive to receptor occupancy. Thus, the Pl(A2) polymorphism altered integrin-mediated functions of adhesion, spreading, actin cytoskeleton rearrangement, and clot retraction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10727448      PMCID: PMC377456          DOI: 10.1172/JCI6982

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Association of the platelet Pl(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bbeta 448 polymorphism with myocardial infarction and extent of coronary artery disease.

Authors:  A M Carter; N Ossei-Gerning; I J Wilson; P J Grant
Journal:  Circulation       Date:  1997-09-02       Impact factor: 29.690

2.  PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis.

Authors:  P M Ridker; C H Hennekens; C Schmitz; M J Stampfer; K Lindpaintner
Journal:  Lancet       Date:  1997-02-08       Impact factor: 79.321

Review 3.  Rho GTPases and the actin cytoskeleton.

Authors:  A Hall
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

4.  Fibrinogen coating density affects the conformation of immobilized fibrinogen: implications for platelet adhesion and spreading.

Authors:  K A Moskowitz; B Kudryk; B S Coller
Journal:  Thromb Haemost       Date:  1998-04       Impact factor: 5.249

5.  RhoA and the function of platelet integrin alphaIIbbeta3.

Authors:  L Leng; H Kashiwagi; X D Ren; S J Shattil
Journal:  Blood       Date:  1998-06-01       Impact factor: 22.113

Review 6.  Human platelet alloantigens.

Authors:  N Valentin; P J Newman
Journal:  Curr Opin Hematol       Date:  1994-09       Impact factor: 3.284

7.  Prothrombotic genetic risk factors in young survivors of myocardial infarction.

Authors:  D Ardissino; P M Mannucci; P A Merlini; F Duca; R Fetiveau; L Tagliabue; M Tubaro; M Galvani; F Ottani; M Ferrario; J Corral; M Margaglione
Journal:  Blood       Date:  1999-07-01       Impact factor: 22.113

8.  Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study.

Authors:  D Feng; K Lindpaintner; M G Larson; V S Rao; C J O'Donnell; I Lipinska; C Schmitz; P A Sutherland; H Silbershatz; R B D'Agostino; J E Muller; R H Myers; D Levy; G H Tofler
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-04       Impact factor: 8.311

9.  A monoclonal antibody (SZ21) specific for platelet GPIIIa distinguishes P1A1 from P1A2.

Authors:  E J Weiss; P J Goldschmidt-Clermont; D Grigoryev; Y Jin; T S Kickler; P F Bray
Journal:  Tissue Antigens       Date:  1995-11

10.  Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis.

Authors:  D H Walter; V Schächinger; M Elsner; S Dimmeler; A M Zeiher
Journal:  Lancet       Date:  1997-10-25       Impact factor: 79.321

View more
  24 in total

1.  The Pl(A2) allele and cardiovascular disease: the pro(33) and con.

Authors:  T V Byzova; E F Plow
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

2.  mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets.

Authors:  Andrew S Weyrich; Melvin M Denis; Hansjorg Schwertz; Neal D Tolley; Jason Foulks; Eliott Spencer; Larry W Kraiss; Kurt H Albertine; Thomas M McIntyre; Guy A Zimmerman
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

3.  Increased activity of phosphatase PP2A in the presence of the PlA2 polymorphism of alphaIIbbeta3.

Authors:  Huili Wang; Bin Yan; Lisa L Satterwhite; Qi Ma; Pascal J Goldschmidt-Clermont
Journal:  Biochem Biophys Res Commun       Date:  2007-12-26       Impact factor: 3.575

4.  Variation in ITGB3 is associated with asthma and sensitization to mold allergen in four populations.

Authors:  Lauren A Weiss; Lucille A Lester; James E Gern; Raoul L Wolf; Rodney Parry; Robert F Lemanske; Julian Solway; Carole Ober
Journal:  Am J Respir Crit Care Med       Date:  2005-04-07       Impact factor: 21.405

5.  A point mutation in the EGF-4 domain of β(3) integrin is responsible for the formation of the Sec(a) platelet alloantigen and affects receptor function.

Authors:  Ulrich J Sachs; Tamam Bakchoul; Olga Eva; Astrid Giptner; Gregor Bein; Richard H Aster; Maria Gitter; Julie Peterson; Sentot Santoso
Journal:  Thromb Haemost       Date:  2011-11-24       Impact factor: 5.249

6.  Variation in ITGB3 has sex-specific associations with plasma lipoprotein(a) and whole blood serotonin levels in a population-based sample.

Authors:  Lauren A Weiss; Mark Abney; Rodney Parry; Angelo M Scanu; Edwin H Cook; Carole Ober
Journal:  Hum Genet       Date:  2005-04-15       Impact factor: 4.132

7.  The human platelet antigen-1b (Pro33) variant of αIIbβ3 allosterically shifts the dynamic conformational equilibrium of this integrin toward the active state.

Authors:  Giulia Pagani; Joana P V Pereira; Volker R Stoldt; Andreas Beck; Rüdiger E Scharf; Holger Gohlke
Journal:  J Biol Chem       Date:  2018-02-09       Impact factor: 5.157

Review 8.  Integrin αIIbβ3: from discovery to efficacious therapeutic target.

Authors:  Kamila Bledzka; Susan S Smyth; Edward F Plow
Journal:  Circ Res       Date:  2013-04-12       Impact factor: 17.367

9.  Elevated lipoprotein(a) levels and homozygous human platelet antigen 1b (HPA-1b) genotype are risk factors for intrauterine growth restriction (IUGR).

Authors:  Andrea Gerhardt; Nadja Howe; Jan Steffen Krüssel; Ruediger Eberhard Scharf; Rainer Bernd Zotz
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

10.  Molecular cloning and expression of glycoprotein IIIa(T1565C).

Authors:  Lei Ren; Limei Zhang; Yanhong Liu
Journal:  Mol Biol Rep       Date:  2008-09-02       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.